- Home
- JRS vs LCTX Comparison
JRS vs LCTX Comparison
Compare JRS & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- LCTX
- Stock Information
- Founded
- JRS 2001
- LCTX 1990
- Country
- JRS United States
- LCTX United States
- Employees
- JRS N/A
- LCTX N/A
- Industry
- JRS Finance/Investors Services
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JRS Finance
- LCTX Health Care
- Exchange
- JRS Nasdaq
- LCTX Nasdaq
- Market Cap
- JRS 231.7M
- LCTX 274.0M
- IPO Year
- JRS N/A
- LCTX N/A
- Fundamental
- Price
- JRS $8.15
- LCTX $1.67
- Analyst Decision
- JRS
- LCTX Strong Buy
- Analyst Count
- JRS 0
- LCTX 4
- Target Price
- JRS N/A
- LCTX $4.25
- AVG Volume (30 Days)
- JRS 86.6K
- LCTX 1.8M
- Earning Date
- JRS 01-01-0001
- LCTX 11-13-2025
- Dividend Yield
- JRS 8.87%
- LCTX N/A
- EPS Growth
- JRS N/A
- LCTX N/A
- EPS
- JRS N/A
- LCTX N/A
- Revenue
- JRS N/A
- LCTX $10,914,000.00
- Revenue This Year
- JRS N/A
- LCTX N/A
- Revenue Next Year
- JRS N/A
- LCTX $176.00
- P/E Ratio
- JRS N/A
- LCTX N/A
- Revenue Growth
- JRS N/A
- LCTX 76.43
- 52 Week Low
- JRS $5.95
- LCTX $0.37
- 52 Week High
- JRS $8.00
- LCTX $1.85
- Technical
- Relative Strength Index (RSI)
- JRS 55.96
- LCTX 54.97
- Support Level
- JRS $7.95
- LCTX $1.63
- Resistance Level
- JRS $8.17
- LCTX $1.83
- Average True Range (ATR)
- JRS 0.11
- LCTX 0.11
- MACD
- JRS 0.00
- LCTX -0.03
- Stochastic Oscillator
- JRS 87.50
- LCTX 26.00
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.